SLDB compared with BCAX: revenue, margins and what each company keeps, and the suppliers and customers both name

SLDBSolid Biosciences Inc.

Mkt capRevenueRevenue

BCAXBicara Therapeutics Inc.

Mkt capRevenueRevenue

Compare

SLDBSolid Biosciences Inc.

BCAXBicara Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SLDB

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q1 FY26±75.6%▲+18.81%×0.25

Q3 FY25±38.3%▼−15.29%×0.40

Feb 18 '25±29.3%▲+31.51%×1.08

Jan 8 '24±15.0%▲+7.59%×0.51

BCAX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26—▼−14.32%—

May 11 '26±19.1%▲+1.51%×0.08

= impliedSLDB realized, solidBCAX realized, hatchedOne scale, both sides: full bar = 76%× = |realized| ÷ impliedspan: SLDB 791d · BCAX 274dSource: market data

Q1 FY26

±13.5%

▲+3.65%

×0.27

Q3 FY25±29.2%▼−4.85%×0.16

SLDBSolid Biosciences Inc.

6.20· pre 6.20· delayed

Mkt cap$664.8M

BCAXBicara Therapeutics Inc.

9.11· pre 8.91· delayed

Pre-marketOct 30 '26delayed

Mkt cap$620.2M

Compare

Pre-marketOct 30 '26delayed

SLDBSolid Biosciences Inc.

BCAXBicara Therapeutics Inc.

6.20pre 6.20delayed

Price

9.11pre 8.91delayed

$664.8M

Mkt cap

$620.2M

SLDB6.20vsBCAX9.11Pre-marketOct 30 '26delayed